British Biobank launches large-scale gene sequencing program
British Biobank has announced that it will work with GlaxoSmithKline Pharmaceuticals (GSK) and Reproductive Pharmaceuticals (RGC) to sequence the 500,000 sample of volunteers owned by the bank; the first batch of 50,000 The gene sequencing of the sample will be completed by the end of this year.
Genetic evidence can provide a clear link between genes and diseases, and in recent years has revolutionized scientific discovery and drug development. 90% of the various potential drugs currently entering the clinical trial phase are unable to confirm their necessary efficiency and safety, and thus fail to enter the patient use phase. Most of the failures are due to the failure to fully understand the relationship between the drug biological target and human disease. Contact. Through comparative research, it is found that the use of human genetic evidence can greatly improve the success rate of drug development.
British Biobank has the most abundant health resources in the world. For more than a decade, the UK Government and the Charity Drug Research Fund have invested £200 million in it, collecting information and samples of 500,000 volunteers, and ensuring that the data provided to researchers is not used to determine the identity of these individuals. The initial funding for this collaboration was jointly invested by RGC and GSK, and the first batch of 50,000 samples was scheduled to be genetically sequenced by the end of 2017. It is expected that the sequencing of all 500,000 volunteer samples in the future will cost £150 million and last for three to five years. GSK and RGC have a nine-month exclusive use of the resulting gene sequencing data, which will then be included in the UK Biobank database, which will eventually open to more scientists and technology organizations; all research findings will also Published to peer-reviewed journals for publication.
Rory Collins, Principal Investigator of the British Biobank and Professor of Medicine and Epidemiology at Oxford University, said: "We look forward to the program's ability to open the door to rapid production of new drugs, and to enable BNP to provide research for health-related research. More help.†Patric, president of GSK's research and development work, overcomes Wallens. “The development of human genomics has profoundly changed our understanding of human biology and is currently in a new era of drug discovery. Together, we are able to enrich this resource and offer potential new opportunities for companies like GSK to develop new drugs."
Our medicinal synthetic polyisoprene gasket for injection does not contain any substances that can easily produce pyrogen. We now use a unique technique to add cytotoxicity to the routine test of butyl rubber stoppers such as pyrogen, hemolysis, acute systemic toxicity test and so on. Systemic injection test and intradermal stimulation test have been used abroad for many years.Our good puncture resistance ensures the minimum rate of chip drop during the puncture process and our good self-sealing performance can guarantee no leakage during using process in hospital.Also,good retention of puncture device ensures that there is no needle slider and needle drop in the process of hospital use.
Isoprene Gasket, Medical Synthetic Isoprene Gasket, Pharmaceutical Polyisoprene Disc, Pharmaceutical Synthetic Disc, Gasket for syringe, syringe piston, syringe rubber
SUZHOU CRH PHARMACEUTICAL TECHNOLOGY CO.,LTD , https://www.crh-health.com